Species differences and substrate specificity of CYP3A heteroactivation by efavirenz

References

• Adkins JC, Noble S. (1998). Efavirenz. Drugs 56:1055–64; discussion 65–6
   PubMed Web of Science ®Google Scholar
• Bayer J, Heinrich T, Burhenne J, et al. (2009). Potential induction of CYP3A4 after a single-dose of efavirenz using midazolam pharmacokinetics as a marker. Basic Clin Pharmacol Toxicol 104:515
   Google Scholar
• Belanger AS, Caron P, Harvey M, et al. (2009). Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug–drug interaction with zidovudine. Drug Metab Dispos 37:1793–6
   PubMed Web of Science ®Google Scholar
• Blobaum AL, Bridges TM, Byers FW, et al. (2013). Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug–drug interactions. Drug Metab Dispos 41:2066–75
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Bertrand M, Jackson P, et al. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–52
   PubMed Web of Science ®Google Scholar
• Cameron MD, Wen B, Allen KE, et al. (2005). Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44:14143–51
   PubMed Web of Science ®Google Scholar
• Egnell AC, Houston B, Boyer S. (2003). In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305:1251–62
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K. (2006). Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug–drug interaction patterns. Xenobiotica 36:219–33
   PubMed Web of Science ®Google Scholar
• Emoto C, Yoda N, Uno Y, et al. (2013). Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters and potential for inhibitory profiles. Curr Drug Metab 14:239–52
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, et al. (1994). Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643–53
   PubMed Web of Science ®Google Scholar
• Hariparsad N, Nallani SC, Sane RS, et al. (2004). Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44:1273–81
   PubMed Web of Science ®Google Scholar
• Heizmann P, Ziegler WH. (1981). Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220–3
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355–62
   PubMed Web of Science ®Google Scholar
• Igarashi T, Sakuma T, Isogai M, et al. (1997). Marmoset liver cytochrome P450s: study for expression and molecular cloning of their cDNAs. Arch Biochem Biophys 339:85–91
   PubMed Web of Science ®Google Scholar
• Ishigami M, Kawabata K, Takasaki W, et al. (2001). Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 29:1068–72
   PubMedGoogle Scholar
• Iwasaki K, Uno Y. (2009). Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica 39:578–81
   PubMed Web of Science ®Google Scholar
• Ji HY, Lee H, Lim SR, et al. (2012). Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6 and 1A9 activities in human liver microsomes. Molecules 17:851–60
   PubMedGoogle Scholar
• Kanazu T, Yamaguchi Y, Okamura N, et al. (2004). Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391–402
   PubMed Web of Science ®Google Scholar
• Kerr BM, Thummel KE, Wurden CJ, et al. (1994). Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969–79
   PubMed Web of Science ®Google Scholar
• Keubler A, Weiss J, Haefeli WE, et al. (2012). Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1′-hydroxylation in vitro. Drug Metab Dispos 40:1178–82
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Domanski TL, Halpert JR. (2002). Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495–506
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. (2008). Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775–800
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Krishnamachary N, Shou M, et al. (1998). Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137–47
   PubMed Web of Science ®Google Scholar
• Kuperman AV, Kalgutkar AS, Marfat A, et al. (2001). Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro–in vivo correlation, gender-related differences, isoform identification and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 29:1403–9
   PubMed Web of Science ®Google Scholar
• Lu C, Li AP. (2001). Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig and beagle dog. Chem Biol Interact 134:271–81
   PubMed Web of Science ®Google Scholar
• Maenpaa J, Hall SD, Ring BJ, et al. (1998). Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137–55
   PubMedGoogle Scholar
• Nakamura A, Hirota T, Morino A, et al. (1999). Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21. Xenobiotica 29:243–52
   PubMed Web of Science ®Google Scholar
• Ngui JS, Tang W, Stearns RA, et al. (2000). Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28:1043–50
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, et al. (2003). Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819–50
   PubMed Web of Science ®Google Scholar
• Niwa T, Murayama N, Yamazaki H. (2008). Heterotropic cooperativity in oxidation mediated by cytochrome p450. Curr Drug Metab 9:453–62
   PubMed Web of Science ®Google Scholar
• Ogasawara A, Kume T, Kazama E. (2007). Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410–18
   PubMed Web of Science ®Google Scholar
• Ogasawara A, Utoh M, Nii K, et al. (2009). Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos 37:122–8
   PubMed Web of Science ®Google Scholar
• Ogawa K, Kato M, Houjo T, Ishigai M. (2013). A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. Xenobiotica 43:468–78
   PubMed Web of Science ®Google Scholar
• Ohtsuka T, Yoshikawa T, Kozakai K, et al. (2010). Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab Dispos 38:1806–13
   PubMed Web of Science ®Google Scholar
• Oswald S, Meyer Zu Schwabedissen HE, Nassif A, et al. (2012). Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther 91:506–13
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Maenpaa J, Taavitsainen P, et al. (1998). Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203–53
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Kuo Y, Tang C, et al. (2006). In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34:1546–55
   PubMed Web of Science ®Google Scholar
• Schwab GE, Raucy JL, Johnson EF. (1988). Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493–9
   PubMed Web of Science ®Google Scholar
• Seo KA, Bae SK, Choi YK, et al. (2010). Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4 and 2B7. Drug Metab Dispos 38:2007–13
   PubMed Web of Science ®Google Scholar
• Sharer JE, Shipley LA, Vandenbranden MR, et al. (1995). Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey and cynomolgus monkey. Drug Metab Dispos 23:1231–41
   PubMed Web of Science ®Google Scholar
• Shou M, Grogan J, Mancewicz JA, et al. (1994). Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450–5
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Fujita K, Murayama N, et al. (2011). Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1′-hydroxylation. Drug Metab Dispos 39:757–62
   PubMed Web of Science ®Google Scholar
• Tang W, Stearns RA. (2001). Heterotropic cooperativity of cytochrome P450 3A4 and potential drug–drug interactions. Curr Drug Metab 2:185–98
   PubMed Web of Science ®Google Scholar
• Tang W, Stearns RA, Kwei GY, et al. (1999). Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068–74
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430
   PubMed Web of Science ®Google Scholar
• Uno Y, Hosaka S, Matsuno K, et al. (2007). Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98–105
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW, et al. (2001). Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 41:85–91
   PubMed Web of Science ®Google Scholar
• Wang RW, Newton DJ, Liu N, et al. (2000). Human cytochrome P-450 3A4: in vitro drug–drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360–6
   PubMed Web of Science ®Google Scholar
• Wiebel FJ, Leutz JC, Diamond L, Gelboin HV. (1971). Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in microsomes from rat tissues: differential inhibition and stimulation by benzoflavones and organic solvents. Arch Biochem Biophys 144:78–86
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–33
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–85
   PubMedGoogle Scholar
• Zhao XJ, Ishizaki T. (1997). The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. J Pharmacol Exp Ther 283:1168–76
   PubMed Web of Science ®Google Scholar
• Zhu B, Bush D, Doss GA, et al. (2008). Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36:331–8
   PubMed Web of Science ®Google Scholar